Compared to our previous findings, we found the opposite effect regarding the β-catenin/RAC1 complex; the fraction, ICC, Co-IP, and ChIP assay results confirmed that the role of KRT19 in different cancers is governed by differential mechanisms (see Figure 5). Here, RAC1 is linked to intrahepatic cholangiocarcinoma.